FR19C1073I2 - Inhibition de l'absorption renale de molecules pouvant potentiellement endommager les reins a l'aide d'une combinaison de lysine et d'arginine - Google Patents

Inhibition de l'absorption renale de molecules pouvant potentiellement endommager les reins a l'aide d'une combinaison de lysine et d'arginine

Info

Publication number
FR19C1073I2
FR19C1073I2 FR19C1073C FR19C1073C FR19C1073I2 FR 19C1073 I2 FR19C1073 I2 FR 19C1073I2 FR 19C1073 C FR19C1073 C FR 19C1073C FR 19C1073 C FR19C1073 C FR 19C1073C FR 19C1073 I2 FR19C1073 I2 FR 19C1073I2
Authority
FR
France
Prior art keywords
arginine
lysine
kidney
inhibition
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR19C1073C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Accelerator Applications USA Inc
Original Assignee
Advanced Accelerator Applications USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Accelerator Applications USA Inc filed Critical Advanced Accelerator Applications USA Inc
Publication of FR19C1073I1 publication Critical patent/FR19C1073I1/fr
Application granted granted Critical
Publication of FR19C1073I2 publication Critical patent/FR19C1073I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR19C1073C 1999-07-16 2019-12-09 Inhibition de l'absorption renale de molecules pouvant potentiellement endommager les reins a l'aide d'une combinaison de lysine et d'arginine Active FR19C1073I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14410699P 1999-07-16 1999-07-16
PCT/EP2000/006917 WO2001005383A2 (en) 1999-07-16 2000-07-17 Inhibition of renal uptake of radiomolecules with a combination of lysine and arginine

Publications (2)

Publication Number Publication Date
FR19C1073I1 FR19C1073I1 (enrdf_load_html_response) 2020-01-17
FR19C1073I2 true FR19C1073I2 (fr) 2020-12-18

Family

ID=22507065

Family Applications (1)

Application Number Title Priority Date Filing Date
FR19C1073C Active FR19C1073I2 (fr) 1999-07-16 2019-12-09 Inhibition de l'absorption renale de molecules pouvant potentiellement endommager les reins a l'aide d'une combinaison de lysine et d'arginine

Country Status (7)

Country Link
EP (1) EP1196154B1 (enrdf_load_html_response)
JP (1) JP2003504395A (enrdf_load_html_response)
AU (1) AU6275800A (enrdf_load_html_response)
CA (1) CA2379696C (enrdf_load_html_response)
DE (1) DE60030722T2 (enrdf_load_html_response)
FR (1) FR19C1073I2 (enrdf_load_html_response)
WO (1) WO2001005383A2 (enrdf_load_html_response)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002275059A (ja) * 2001-03-15 2002-09-25 Inst Of Physical & Chemical Res 腎機能障害改善用アミノ酸組成物
FI20010764A0 (fi) * 2001-04-11 2001-04-11 Map Medical Technologies Oy Kationiset dekstraanijohdannaiset käytettäväksi munuaisten suojaamiseen
US7345018B2 (en) 2002-04-25 2008-03-18 Reception Aps Method of treating side effects induced by therapeutic agents
WO2003080103A1 (en) * 2002-04-25 2003-10-02 Recepticon Aps Antagonists of megalin or cubilin for use in preventing organ damage induced by therapeutic agents
EP1462119A1 (en) * 2003-03-24 2004-09-29 Schering AG Modulators of the megalin-mediated uptake of radiotherapeutics and/or radiodiagnostics into kidney cells and their use in therapy and diagnostics
WO2004084953A1 (en) * 2003-03-24 2004-10-07 Schering Ag Modulators of the megalin-mediated uptake of radiotherapeutics and/or radiodiagnostics into kidney cells and their use in therapy and diagnostics
JP2006199668A (ja) * 2005-01-24 2006-08-03 Hiroshima Univ 腎毒性抑制剤として利用できる新規ペプチドおよびこれを用いた腎毒性抑制剤、並びにこれを用いた抗菌製剤
EP1862172A1 (en) 2006-05-31 2007-12-05 BioSynthema Inc. Combination of amino acid solution and a gelatin for inhibiting renal uptake
JP5721106B2 (ja) * 2009-07-31 2015-05-20 国立研究開発法人理化学研究所 膵臓内分泌細胞用指示薬、及びその利用
RU2528414C1 (ru) * 2013-01-25 2014-09-20 Закрытое Акционерное Общество "Фарм-Синтез" Циклический октапептид, радиофармацевтическое средство на его основе и способ применения радиофармацевтического средства для получения лекарственных (фармацевтических) средств для лечения новообразований, экспрессирующих соматостатиновые рецепторы
WO2020224780A1 (en) 2019-05-08 2020-11-12 ITM Isotopen Technologien München AG Para-aminohippuric acid (pah) as a renal protective substance
CN115003311B (zh) * 2019-12-14 2024-04-19 乔杜里·马努 降低多器官毒性的多元药物制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991004755A1 (en) * 1989-09-29 1991-04-18 Neorx Corporation Methods for reducing non-target retention of immunoconjugates and metabolites thereof
US5843894A (en) * 1995-03-21 1998-12-01 Center For Molecular Medicine And Immunology Methods for reduced renal uptake of antibody fragments
US5728678A (en) * 1995-06-06 1998-03-17 Nestec Ltd. Method and composition for providing nutrition to a renal failure patient
WO1997046099A1 (en) * 1996-06-06 1997-12-11 Neorx Corporation Liver retention clearing agents

Also Published As

Publication number Publication date
JP2003504395A (ja) 2003-02-04
EP1196154A2 (en) 2002-04-17
CA2379696C (en) 2009-09-15
EP1196154B1 (en) 2006-09-13
DE60030722D1 (de) 2006-10-26
WO2001005383A2 (en) 2001-01-25
FR19C1073I1 (enrdf_load_html_response) 2020-01-17
AU6275800A (en) 2001-02-05
WO2001005383A3 (en) 2001-07-19
CA2379696A1 (en) 2001-01-25
DE60030722T2 (de) 2007-09-20

Similar Documents

Publication Publication Date Title
FR19C1073I2 (fr) Inhibition de l'absorption renale de molecules pouvant potentiellement endommager les reins a l'aide d'une combinaison de lysine et d'arginine
EP1346724A4 (en) AGENT FOR TREATING HEPATITIS C
FR2808068B1 (fr) Joint d'etancheite metallique
MA26822A1 (fr) Composes pour le traitement d'une ischemie.
DE50002679D1 (de) Rohrverbindung
DE60039206D1 (de) Neue Quinazolin-Derivate
FR2813375B1 (fr) Element filete pour joint filete tubulaire resistant au grippage
NO981344D0 (no) Rörkopling
DE60028295D1 (de) Rohrkupplung
ATE278143T1 (de) Rohrverbindung mit integriertem gewinde
DE60018858D1 (de) Rohrkupplung
DE69938819D1 (de) Rohrschelle
IT1313205B1 (it) Giunto con migliorata stabilita' di frenatura e minore deformazioneper eccessivo serraggio.
FR2797208B1 (fr) Element antivibrations pourvu d'une surete d'arrachement
DE69931773D1 (de) Rohrverbindung
MA25834A1 (fr) Utilisation d'une combinaison de salmeterol et de propionate de fluticasone.
FR2819563B1 (fr) Visco-accouplement avec frein pour sa bague d'accouplement
NO20005314L (no) Sandbestandig fluidsvivel
DE69921499D1 (de) Flüssigkeitsdichte Kupplung
FR2758854B1 (fr) Joint souple permettant le calfeutrement d'une saignee de drainage amenagee dans une paroi, notamment dans la paroi d'un tunnel
FR2790805B1 (fr) Ensemble d'accouplement
FI20000433A0 (fi) Putkiliitos
ATE237420T1 (de) Giessrohr
FR2793472B1 (fr) Conditionnement en deux parties emboitables l'une dans l'autre
DE50005575D1 (de) Rohrschelle